The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Patients treated with a tumor necrosis factor-${\alpha}$ inhibitor are more likely to develop extrapulmonary tuberculosis

  • Lee, Sang-Oh (Department of Internal Medicine, University of Ulsan College of Medicine)
  • Published : 2013.03.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206. https://doi.org/10.1183/09031936.00028510
  2. Maini R, St Clair EW, Breedveld F, et al. Inf liximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999;354:1932-1939. https://doi.org/10.1016/S0140-6736(99)05246-0
  3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inf liximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001;345:1098-1104. https://doi.org/10.1056/NEJMoa011110
  4. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-1855. https://doi.org/10.1128/IAI.69.3.1847-1855.2001
  5. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-711.
  6. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-${\alpha}$ inhibitor. Korean J Intern Med 2013;28:174-179. https://doi.org/10.3904/kjim.2013.28.2.174
  7. Canet E, Dantal J, Blancho G, Hourmant M, Coupel S. Tuberculosis following kidney transplantation: clinical features and outcome: a French multicentre experience in the last 20 years. Nephrol Dial Transplant 2011;26:3773-3778. https://doi.org/10.1093/ndt/gfr156
  8. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009;15:894-906. https://doi.org/10.1002/lt.21709
  9. Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779-783. https://doi.org/10.3346/jkms.2007.22.5.779
  10. Hur JA, Seo SH, Park SH, Cho CS, Kim HY. Discrepancy between the tuberculin skin test and the T-SPOT.TB for detecting latent Mycobacterium tuberculosis infection in patients with rheumatoid arthritis. J Korean Rheum Assoc 2006;13:285-290.

Cited by

  1. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols vol.559, pp.None, 2013, https://doi.org/10.1016/j.abb.2014.06.006